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Abstract
Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs)
for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need
for complementary assays to detect small, but potentially important, phenotypic differences
between control iPSC lines and those carrying disease mutations.
In their recent study, Egawa et al. (1) analyse motor neurons differentiated from iPSC lines
derived from patients with amyotrophic lateral sclerosis (ALS) carrying mutations in
TDP-43 (1). Using multiple mutant TDP-43 iPSC lines, they confirm and extend in detail
the in vitro recapitulation of ALS-associated phenotypes that we had shown previously (2).
In contrast to our findings (2), Egawa et al. state that they do not observe a survival
difference between cultured motor neurons derived from mutant TDP-43 iPSC lines versus
control iPSC lines under basal conditions when using a lactate dehydrogenase (LDH) release
assay to measure neuronal survival [Fig. S11C in (1)]. In our study (2), we did not make any
claims about the survival of iPSC-derived mutant ALS and control motor neurons under
basal conditions measured using the LDH assay. However, we did report a survival
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difference when using the LDH release assay in the presence of a stressor [Fig. 5C in (2)]
and also when using real-time single-cell longitudinal survival analysis under basal
conditions [Fig. 5B in (2)]. We would like to clarify this issue as well as discuss the value of
using complementary survival analysis methods.
Specifically, in our study we aimed to address two issues regarding the effect of the M337V
TDP-43 mutation on motor neuron survival (2). To address whether the M337V mutation
caused an inherent neuronal vulnerability under basal conditions we used real-time single-
cell longitudinal image analysis in which only the neurons that expressed a fluorescent
reporter construct on the first day of the assay were followed serially and monitored for
survival over 10 days [Fig. 5B in (2)]. Next, we investigated at the population level whether
the TDP-43 mutation conferred a selective sensitivity to a stressor, which was assessed by a
fluorometric cytotoxicity assay that measured LDH enzyme released into the culture
medium by neurons that had lost membrane integrity [Fig. 5C in (2)]. Given the dynamic
nature of iPSC-derived neuronal populations, a certain level of cell death and limited
proliferation of residual neural progenitors are expected and this background activity can
potentially mask subtle differences in survival. In fact, a breakdown of our control LDH
release assay data (Fig. 1A, this letter), also does not reveal a difference in survival between
M337V mutant or control iPSC-derived motor neurons under basal conditions, which is in
agreement with Egawa et al.’s results [Fig. S11C in (1)].
The challenge of elucidating subtle but significant phenotypes in long-term neuronal
cultures requires the application of multiple complementary readouts. Real-time single-cell
longitudinal survival analysis using fluorescent reporter genes has enabled determination of
differences in neuronal survival that may otherwise have been missed using conventional
population-based assays such as the LDH release assay (3, 4). Another method to determine
survival differences between different populations is to count cells that are positive for a
particular reporter/marker at discrete time-points. Survival analysis performed by
fluorescent reporter-based “snapshot” cell counts at fixed time points can also present
challenges of interpretation because upon transient transfection fluorescent reporters can be
expressed stochastically over the time course of the experiment. To test this possibility, we
counted daily for nine days the number of green fluorescent protein (GFP)-positive cultured
neurons derived from control iPSCs transfected with a motor neuron-specific HB9::GFP
reporter construct. We used this approach instead of performing real-time survival analysis
in which we only followed individual neurons that were GFP-positive on day 1 and recorded
their time of death [Fig. 5B in (2)]. Our analysis revealed that the total number of GFP-
positive motor neurons fluctuated over the course of nine days under basal conditions and
did not differ significantly from day 1 (Fig. 1B; this letter). However, real-time single-cell
longitudinal survival analysis using the same experimental setup did reveal an increased risk
of neuronal death in control iPSC-derived motor neurons over time [Fig. 5B in (2)].
Rapid developments in iPSC technology now enable the comparison of cellular phenotypes
between iPSC lines carrying a mutation versus control lines that do not. Real-time single-
cell longitudinal survival analysis is a sensitive method for detecting phenotypes that may
otherwise be masked due to variability arising from static measurements. The utility of this
approach has recently been confirmed in Huntington’s disease patient-derived iPSC
neuronal cultures (5). This study revealed a higher cumulative risk of death in neurons
derived from iPSCs with CAG-repeat expansions compared to control iPSCs under basal
conditions (5). We agree with Egawa et al. regarding the importance of independent multiple
clonal line-based confirmation of phenotypic differences identified for any given disease
mutation. Indeed, such studies would also benefit from the use of complementary sensitive
assays to identify potentially important survival phenotypes.
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Fig. 1. Survival of ALS mutant versus control iPSC-derived motor neurons
(A) Comparison of cell death in motor neuronal cultures derived from two clones of mutant
M337V TDP-43 iPSCs from one ALS patient (M337V-1 and M337V-2) and two control
iPSC lines (from two different individuals; Control-1 and Control-2) under basal conditions
using an LDH release assay (2). LDH release into the culture medium was normalized to
total LDH after cell lysis for each well to determine percent cytotoxicity. Values are mean ±
SEM. Data were analyzed by one-way ANOVA. There were no significant differences
between the mean survival for motor neurons derived from mutant M337V TDP-43 iPSCs
versus control iPSCs (n=4). (B) Cell survival of two independent control iPSC-derived
motor neuronal cultures transfected with a HB9::GFP reporter construct. Cell survival was
measured by counting the number of GFP-positive neurons over the course of nine days (2).
The cell count on day 1 for each experiment was set to 100% and each time point after that
was expressed as a percent of the value at day 1. Values are mean ± SEM, n=4. There were
no significant differences in mean survival between day 1 and day 9.
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